Ranibizumab as intravitreal injections is in clinical development for the treatment of diabetic retinopathy in both its proliferative and non-proliferative forms. Diabetic retinopathy, is a disease that affect the retinas and other parts of the inner eye. It is a chronic progressive condition of the retinal blood vessels due to prolonged raised blood glucose. When new blood vessels and scar tissue form on the retina causing bleeding within the eye and loss of vision, it is called proliferative diabetic retinopathy.
Ranibizumab has been designed to block a substance called vascular endothelial growth factor A (VEGF‑A), a protein that helps blood vessels grow and leak fluid and blood. By blocking this factor, ranibizumab reduces the growth of the blood vessels and controls the leakage and swelling in the retina. If licensed for diabetic retinopathy, ranibizumab has the potential to neutralise the retinal macular degeneration and reverse disease progression.
Abicipar pegol is a novel therapeutic approach that uses a new generation of genetically engineered proteins that exhibit highly specific and high‐affinity target protein binding. As
an anti‐VEGF‐A, it works by inhibiting the growth of immature blood vessels that grow in the retina, reducing the haemorrhaging and scarring that leads to vision impairment. Abicipar
pegol has the potential to require less frequent injections into the eye than the current standard of care, while providing equal improvements in vision. If licensed this could be an effective treatment option with greater compliance for patients with wet age‐related macular degeneration.